Insider filing · NUVL
James E Flynn
Director
profile →
Nuvalent Inc
NUVL · Healthcare · 94 filings in 24 months
ticker →
James E Flynn sold $70.9M of Nuvalent (NUVL)
Executed Nov 24 2025, disclosed Nov 24 2025, the same day.
Value, as filed
$70.9M
742,574 sh across 2 lots
Executed
Nov 24 2025
the trade date, as filed
Disclosed
Nov 24 2025
0 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JFJames E Flynn (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Larimar Therapeutics, Inc. (LRMR). Across 1 priced purchase filing, the average 21-session return was -16.6% from execution and -14.2% from disclosure (delay-adjusted; derived). The largest single filing was $70.9M of NUVL (742,574 sh across 2 lots, as filed), executed Nov 24 2025.
The name
NUVLHealthcare · Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→